228 related articles for article (PubMed ID: 16079121)
21. Alemtuzumab: what is the secret to safe therapy?
Elter T; Hallek M; Montillo M
Clin Adv Hematol Oncol; 2011 May; 9(5):364-73. PubMed ID: 21685865
[TBL] [Abstract][Full Text] [Related]
22. Alemtuzumab for B-cell chronic lymphocytic leukemia.
Robak T
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1033-51. PubMed ID: 18588450
[TBL] [Abstract][Full Text] [Related]
23. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.
Rai KR; Freter CE; Mercier RJ; Cooper MR; Mitchell BS; Stadtmauer EA; Santábarbara P; Wacker B; Brettman L
J Clin Oncol; 2002 Sep; 20(18):3891-7. PubMed ID: 12228210
[TBL] [Abstract][Full Text] [Related]
24. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG).
Schweighofer CD; Ritgen M; Eichhorst BF; Busch R; Abenhardt W; Kneba M; Hallek M; Wendtner CM
Br J Haematol; 2009 Jan; 144(1):95-8. PubMed ID: 19016732
[TBL] [Abstract][Full Text] [Related]
25. An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients.
Cortelezzi A; Gritti G; Laurenti L; Cuneo A; Ciolli S; Di Renzo N; Musto P; Mauro FR; Cascavilla N; Falchi L; Zallio F; Callea V; Maura F; Martinelli S; Piciocchi A; Reda G; Foà R;
Br J Haematol; 2012 Feb; 156(4):481-9. PubMed ID: 22150204
[TBL] [Abstract][Full Text] [Related]
26. Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab.
Vallejo C; Ríos E; de la Serna J; Jarque I; Ferrá C; Sánchez-Godoy P; Solano C; de la Cámara R; Rosell AI; Varela R; García MD; González-Barca E; López J; Pérez E; Ferrer S; Casado LF; Vázquez L; Villalón L; García-Marco JA
Expert Rev Hematol; 2011 Feb; 4(1):9-16. PubMed ID: 21322774
[TBL] [Abstract][Full Text] [Related]
27. A case report of successful alemtuzumab treatment of a B-CLL patient suffering from renal failure.
Haslbauer F
Ann Hematol; 2009 Apr; 88(4):399-400. PubMed ID: 19099306
[No Abstract] [Full Text] [Related]
28. Advances in the use of alemtuzumab in CLL.
Stilgenbauer S
Clin Adv Hematol Oncol; 2008 Jan; 6(1):23-4. PubMed ID: 18322437
[No Abstract] [Full Text] [Related]
29. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome.
Montillo M; Schinkoethe T; Elter T
Cancer Invest; 2005; 23(6):488-96. PubMed ID: 16203656
[TBL] [Abstract][Full Text] [Related]
30. The emerging role of alemtuzumab in chronic lymphocytic leukemia.
Nabhan C
Clin Lymphoma Myeloma; 2005 Sep; 6(2):115-21. PubMed ID: 16231849
[TBL] [Abstract][Full Text] [Related]
31. Mycobacterium avium complex infection after alemtuzumab therapy for chronic lymphocytic leukemia.
Saadeh CE; Srkalovic G
Pharmacotherapy; 2008 Feb; 28(2):281-4. PubMed ID: 18225973
[TBL] [Abstract][Full Text] [Related]
32. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody).
Karlsson C; Hansson L; Celsing F; Lundin J
Leukemia; 2007 Mar; 21(3):511-4. PubMed ID: 17215854
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of alemtuzumab after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab with or without CD52-positive malignancies.
Oshima K; Kanda Y; Nakahara F; Shoda E; Suzuki T; Imai Y; Watanabe T; Asai T; Izutsu K; Ogawa S; Motokura T; Chiba S; Kurokawa M
Am J Hematol; 2006 Nov; 81(11):875-9. PubMed ID: 16862551
[TBL] [Abstract][Full Text] [Related]
34. Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study.
Cortelezzi A; Pasquini MC; Gardellini A; Gianelli U; Bossi A; Reda G; Sarina B; Musto P; Barcellini W; Neri A; Deliliers GL
Leukemia; 2009 Nov; 23(11):2027-33. PubMed ID: 19641526
[TBL] [Abstract][Full Text] [Related]
35. CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond.
Dumont FJ
Expert Rev Anticancer Ther; 2002 Feb; 2(1):23-35. PubMed ID: 12113063
[TBL] [Abstract][Full Text] [Related]
36. Antibody therapy for chronic lymphocytic leukemia: a promising new modality.
Lin TS; Moran M; Lucas M; Waymer S; Jefferson S; Fischer DB; Grever MR; Byrd JC
Hematol Oncol Clin North Am; 2004 Aug; 18(4):895-913, ix-x. PubMed ID: 15325705
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia--change of regimen needed?
Rieger K; Von Grünhagen U; Fietz T; Thiel E; Knauf W
Leuk Lymphoma; 2004 Feb; 45(2):345-9. PubMed ID: 15101722
[TBL] [Abstract][Full Text] [Related]
38. Cutaneous cryptococcosis with alemtuzumab in a patient treated for chronic lymphocytic leukaemia.
Dilhuydy MS; Jouary T; Demeaux H; Ravaud A
Br J Haematol; 2007 Jun; 137(6):490. PubMed ID: 17425643
[No Abstract] [Full Text] [Related]
39. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
Robak T
Transfus Apher Sci; 2005 Feb; 32(1):33-44. PubMed ID: 15737872
[TBL] [Abstract][Full Text] [Related]
40. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Vazquez ER; Spigel DR; Raefsky E; Bearden JD; Saez RA; Greco FA
Cancer; 2008 Mar; 112(6):1288-95. PubMed ID: 18189296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
